Literature DB >> 3349931

Record linkage studies for postmarketing drug surveillance: data quality and validity considerations.

A S Stergachis1.   

Abstract

Large automated databases are the source of information for many record linkage studies, including postmarketing drug surveillance. Despite this reliance on prerecorded data, there have been few attempts to assess data quality and validity. This article presents some of the basic data quality and validity issues in applying record linkage methods to postmarketing surveillance. Studies based on prerecorded data, as in most record linkage studies, have all the inherent problems of the data from which they are derived. Sources of threats to the validity of record linkage studies include the completeness of data, the ability to accurately identify and follow the records of individuals through time and place, and the validity of data. This article also describes techniques for evaluating data quality and validity. Postmarketing surveillance could benefit from more attention to identifying and solving the problems associated with record linkage studies.

Mesh:

Year:  1988        PMID: 3349931     DOI: 10.1177/106002808802200216

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  8 in total

1.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  Impact of drug usage review on drug utilisation.

Authors:  J L Blackburn
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

3.  Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?

Authors:  Barbara P Yawn; Peter Wollan; Jennifer St Sauver
Journal:  Am J Epidemiol       Date:  2011-09-13       Impact factor: 4.897

Review 4.  Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.

Authors:  Elisabetta Patorno; Elizabeth M Garry; Amanda R Patrick; Sebastian Schneeweiss; Victoria G Gillet; Olesya Zorina; Dorothee B Bartels; John D Seeger
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 5.  Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.

Authors:  Elisabetta Patorno; Amanda R Patrick; Elizabeth M Garry; Sebastian Schneeweiss; Victoria G Gillet; Dorothee B Bartels; Elvira Masso-Gonzalez; John D Seeger
Journal:  Diabetologia       Date:  2014-09-12       Impact factor: 10.122

Review 6.  Data quality management in pharmacovigilance.

Authors:  Marie Lindquist
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

7.  Limitations for health research with restricted data collection from UK primary care.

Authors:  Helen Strongman; Rachael Williams; Wilhelmine Meeraus; Tarita Murray-Thomas; Jennifer Campbell; Lucy Carty; Daniel Dedman; Arlene M Gallagher; Jessie Oyinlola; Antonis Kousoulis; Janet Valentine
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-04-16       Impact factor: 2.890

8.  Are women with major depression in pregnancy identifiable in population health data?

Authors:  Lyn Colvin; Linda Slack-Smith; Fiona J Stanley; Carol Bower
Journal:  BMC Pregnancy Childbirth       Date:  2013-03-12       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.